Alligator Bioscience AB (publ) ATORX.ST Stock
Alligator Bioscience AB (publ) Price Chart
Alligator Bioscience AB (publ) ATORX.ST Financial and Trading Overview
| Alligator Bioscience AB (publ) stock price | 1.08 SEK |
| Previous Close | 0.66 SEK |
| Open | 0.66 SEK |
| Bid | 0.62 SEK x 0 |
| Ask | 0.62 SEK x 0 |
| Day's Range | 0.58 - 0.66 SEK |
| 52 Week Range | 0.45 - 2.75 SEK |
| Volume | 3.25M SEK |
| Avg. Volume | 1.84M SEK |
| Market Cap | 224.2M SEK |
| Beta (5Y Monthly) | 1.147126 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.55 SEK |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.87 SEK |
ATORX.ST Valuation Measures
| Enterprise Value | 123.63M SEK |
| Trailing P/E | N/A |
| Forward P/E | -0.74216866 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 5.542157 |
| Price/Book (mrq) | 5.133333 |
| Enterprise Value/Revenue | 3.056 |
| Enterprise Value/EBITDA | -0.594 |
Trading Information
Alligator Bioscience AB (publ) Stock Price History
| Beta (5Y Monthly) | 1.147126 |
| 52-Week Change | -57.54% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.75 SEK |
| 52 Week Low | 0.45 SEK |
| 50-Day Moving Average | 0.62 SEK |
| 200-Day Moving Average | 1.37 SEK |
ATORX.ST Share Statistics
| Avg. Volume (3 month) | 1.84M SEK |
| Avg. Daily Volume (10-Days) | 2.89M SEK |
| Shares Outstanding | 363.96M |
| Float | 139.6M |
| Short Ratio | N/A |
| % Held by Insiders | 17.36% |
| % Held by Institutions | 3.90% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -523.73% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -63.49% |
| Return on Equity (ttm) | -160.63% |
Income Statement
| Revenue (ttm) | 40.45M SEK |
| Revenue Per Share (ttm) | 0.18 SEK |
| Quarterly Revenue Growth (yoy) | 83.09% |
| Gross Profit (ttm) | -111724000 SEK |
| EBITDA | -208114000 SEK |
| Net Income Avi to Common (ttm) | -212870000 SEK |
| Diluted EPS (ttm) | -0.72 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 44.84M SEK |
| Total Cash Per Share (mrq) | 0.2 SEK |
| Total Debt (mrq) | 23.32M SEK |
| Total Debt/Equity (mrq) | 87.92 SEK |
| Current Ratio (mrq) | 0.931 |
| Book Value Per Share (mrq) | 0.12 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -177212000 SEK |
| Levered Free Cash Flow (ttm) | -99520872 SEK |
Profile of Alligator Bioscience AB (publ)
| Country | Sweden |
| State | N/A |
| City | Lund |
| Address | Medicon Village |
| ZIP | 223 81 |
| Phone | 46 4 65 40 82 00 |
| Website | https://www.alligatorbioscience.se |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 58 |
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. The company's product portfolio includes Mitazalimab, an agonistic antibody that targets CD40, which is in phase 2 clinical trail for the treatment solid metastatic tumors, initially pancreatic cancer; and ATOR-4066, a bispecific antibody tumor-specific immune effect, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage. It also offers ATOR-1017, a 4-1BB for solid metastatic tumors which is in Phase 1 clinical trial; and ALG.APV-527, which is in phase 2 clinical trail drug that target tumor-associated antigen 4-1BB and 5T4. In addition, the company develops products using its technology platforms, including ALLIGATOR-GOLD and ALLIGATOR-FAB, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. Further, it has collaboration and out-licensing agreements with Aptevo Therapeutics, Inc.; Orion Corporation.; MacroGenics, Inc.; Biotheus; and Abclon. The company was incorporated in 2000 and is headquartered in Lund, Sweden.
Q&A For Alligator Bioscience AB (publ) Stock
What is a current ATORX.ST stock price?
Alligator Bioscience AB (publ) ATORX.ST stock price today per share is 1.08 SEK.
How to purchase Alligator Bioscience AB (publ) stock?
You can buy ATORX.ST shares on the Stockholm exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Alligator Bioscience AB (publ)?
The stock symbol or ticker of Alligator Bioscience AB (publ) is ATORX.ST.
Which industry does the Alligator Bioscience AB (publ) company belong to?
The Alligator Bioscience AB (publ) industry is Biotechnology.
How many shares does Alligator Bioscience AB (publ) have in circulation?
The max supply of Alligator Bioscience AB (publ) shares is 657.95M.
What is Alligator Bioscience AB (publ) Price to Earnings Ratio (PE Ratio)?
Alligator Bioscience AB (publ) PE Ratio is now.
What was Alligator Bioscience AB (publ) earnings per share over the trailing 12 months (TTM)?
Alligator Bioscience AB (publ) EPS is -0.55 SEK over the trailing 12 months.
Which sector does the Alligator Bioscience AB (publ) company belong to?
The Alligator Bioscience AB (publ) sector is Healthcare.
Alligator Bioscience AB (publ) ATORX.ST included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| OMX_Nordic_Small_Cap_SEK_GI OMXNSCSEKGI | 435.1 SEK 42.47 USD |
-0.21
|
— — | — — | — — | — - | — — |
| OMX_Nordic_Small_Cap_EUR_GI OMXNSCEURGI | 349.01 EUR 381.52 USD |
-0.71
|
— — | — — | — — | — - | — — |
| OMX Affarsvarldens Generalindex OMXAFGX | 923.83 SEK 90.18 USD |
-0.03
|
— — | — — | — — | — - | — — |
| OMX Stockholm Health Care PI SX20PI | 3276.93 SEK 319.87 USD |
-0.07
|
— — | — — | — — | — - | — — |
| OMX Stockholm Pharmaceuticals a SX201030PI | 5132.25 SEK 500.97 USD |
+0.49
|
— — | — — | — — | — - | — — |
| OMX_Stockholm_Small_Cap_PI OMXSSCPI | 1196.96 SEK 116.84 USD |
-0.26
|
— — | — — | — — | — - | — — |
| OMX Stockholm_PI OMXSPI | 947.32 SEK 92.47 USD |
-0.04
|
— — | — — | — — | — - | — — |
| OMX Stockholm All-Share Cap_GI OMXSCAPGI | 456.92 SEK 44.6 USD |
+0.02
|
— — | — — | — — | — - | — — |
| OMX_Nordic_Small_Cap_ISK_GI OMXNSCISKGI | 517.93 ISK 3.81 USD |
-0.71
|
— — | — — | — — | — - | — — |
| OMX_Nordic_Small_Cap_DKK_GI OMXNSCDKKGI | 349.16 DKK 51.19 USD |
-0.69
|
— — | — — | — — | — - | — — |
| OMX Stockholm Health Care PI SX4000PI | 2712.52 SEK 264.78 USD |
<0.01
|
— — | — — | — — | — - | — — |
| OMX Stockholm Health Care GI SX20GI | 4204.43 SEK 410.4 USD |
-0.07
|
— — | — — | — — | — - | — — |
| OMX Stockholm Pharmaceuticals a SX201030GI | 6954.45 SEK 678.84 USD |
+0.49
|
— — | — — | — — | — - | — — |
| OMX_Stockholm_Small_Cap_GI OMXSSCGI | 596.42 SEK 58.22 USD |
-0.19
|
— — | — — | — — | — - | — — |
| OMX Stockholm_GI OMXSGI | 466.5 SEK 45.54 USD |
+0.02
|
— — | — — | — — | — - | — — |
- {{ link.label }} {{link}}